Janux Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
JANX$12.04-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Statements of Stockholders’ Equity
For the Nine Months Ended September 30, 2024 and 2023
(in thousands, except share data)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balance at December 31, 2023 | 46,252,440 | $46 | $512,401 | $665 | $(168,763) | $344,349 |
| Issuance of common stock and pre-funded common stock warrants, net of $20,913 of issuance costs | 5,397,301 | 5 | 320,054 | — | — | 320,059 |
| Exercise of common stock options | 613,132 | 1 | 6,052 | — | — | 6,053 |
| Issuance of common stock upon vesting of restricted stock units | 2,500 | — | — | — | — | — |
| Shares issued under employee stock purchase plan | 63,070 | — | 473 | — | — | 473 |
| Vesting of restricted shares | 8,796 | — | 13 | — | — | 13 |
| Stock-based compensation | — | — | 26,769 | — | — | 26,769 |
| Unrealized gain on available-for-sale securities, net | — | — | — | 7,166 | — | 7,166 |
| Net loss | — | — | — | — | (48,778) | (48,778) |
| Balance at September 30, 2024 | 52,337,239 | $52 | $865,762 | $7,831 | $(217,541) | $656,104 |
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance at December 31, 2022 | 41,616,260 | $42 | $432,703 | $(1,535) | $(110,470) | $320,740 |
| Issuance of common stock and pre-funded common stock warrants, net of issuance costs | 4,153,717 | 4 | 56,526 | — | — | 56,530 |
| Exercise of pre-funded common stock warrants | 80,257 | — | — | — | — | — |
| Exercise of common stock options | 191,879 | — | 1,659 | — | — | 1,659 |
| Shares issued under employee stock purchase plan | 57,911 | — | 528 | — | — | 528 |
| Vesting of restricted shares | 51,403 | — | 144 | — | — | 144 |
| Stock-based compensation | — | — | 15,522 | — | — | 15,522 |
| Unrealized gain on available-for-sale securities, net | — | — | — | 360 | — | 360 |
| Net loss | — | — | — | — | (46,535) | (46,535) |
| Balance at September 30, 2023 | 46,151,427 | $46 | $507,082 | $(1,175) | $(157,005) | $348,948 |
Unaudited Condensed Statements of Stockholders’ Equity
For the Three Months Ended September 30, 2024 and 2023
(in thousands, except share data)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at June 30, 2024 | 52,162,215 | $52 | $848,723 | $(1,616) | $(189,482) | $657,677 |
| Exercise of common stock options | 171,764 | — | 1,649 | — | — | 1,649 |
| Issuance of common stock upon vesting of restricted stock units | 2,500 | — | — | — | — | — |
| Vesting of restricted shares | 760 | — | 3 | — | — | 3 |
| Stock-based compensation | — | — | 15,387 | — | — | 15,387 |
| Unrealized gain on available-for-sale securities, net | — | — | — | 9,447 | — | 9,447 |
| Net loss | — | — | — | — | (28,059) | (28,059) |
| Balance at September 30, 2024 | 52,337,239 | $52 | $865,762 | $7,831 | $(217,541) | $656,104 |
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balance at June 30, 2023 | 41,867,536 | $42 | $445,924 | $(1,060) | $(145,437) | $299,469 |
| Issuance of common stock and pre-funded common stock warrants, net of issuance costs | 4,153,717 | 4 | 56,526 | — | — | 56,530 |
| Exercise of pre-funded common stock warrants | 80,257 | — | — | — | — | — |
| Exercise of common stock options | 43,230 | — | 79 | — | — | 79 |
| Vesting of restricted shares | 6,687 | — | 5 | — | — | 5 |
| Stock-based compensation | — | — | 4,548 | — | — | 4,548 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (115) | — | (115) |
| Net loss | — | — | — | — | (11,568) | (11,568) |
| Balance at September 30, 2023 | 46,151,427 | $46 | $507,082 | $(1,175) | $(157,005) | $348,948 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.